Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Verona Pharma plc

Verona Pharma plc (VRNA) Stock Overview

Explore Verona Pharma plc’s financial performance, market position, analyst ratings, and future outlook.

VRNA●NASDAQ
HealthcareBiotechnology
$106.91
$0.12(0.11%)
U.S. Market is Open · 15:17

Verona Pharma plc (VRNA)

Meyka AI Score

Z

Key Financials

Market Cap72.7B
P/E Ratio-2155.44
EPS (TTM)$-1.04
ROE-0.02%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$170.90

VRNA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Verona Pharma plc (NASDAQ: VRNA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Verona Pharma plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VRNA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $170.90 for the NASDAQ listing.

Key metrics behind Verona Pharma plc's NASDAQ-traded stock include a P/E ratio of -2155.44 and a market capitalization of 72.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VRNA on the NASDAQ.

Price Performance (NASDAQ: VRNA)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
1.44%
6-Month Change
52.58%
Year-to-Date (YTD) Change
121.80%
1-Year Change
184.41%
3-Year Change
747.15%
5-Year Change
1684.81%
All-Time (Max) Change
691.93%

Contact Information

https://www.veronapharma.com
44 20 3283 4200
3 More London Riverside, London, NaN, SE1 2RE

Company Facts

2,090 Employees
IPO DateApr 28, 2017
CountryGB

Frequently Asked Questions